Arca
Skip to content
Tools
Tools

Systemic mastocytosis

Drug research and approvals for systemic mastocytosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 12 studies of systemic mastocytosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 4 approved and 0 open orphan designations naming it.

  • Recruiting worldwide: 12
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 4
  • EU medicines: 0

Recruiting now

Newest posted first, of 12 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

  • MidostaurinTyrosine-protein kinase receptor FLT3 inhibitor

Phase 3 1

  • MasitinibFibroblast growth factor receptor 3 inhibitor

Phase 2 9

Phase 1 or earlier 4

How its trials ended

50 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 11 whose ending is known, 45% met their primary endpoint, 9% missed it and 45% stopped early.

  • Completed, result not reported1836%
  • Ongoing1734%
  • Met its primary endpoint510%
  • Status unknown48%
  • Stopped: other or unclear36%
  • Missed its primary endpoint12%
  • Stopped: enrollment or feasibility12%
  • Stopped: funding12%

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 27, 2024A phase 2 multicenter study of TL-895 in subjects with myelofibrosis, indolent systemic mastocytosis, monoclonal mast cell activation syndrome, or…TL-895 (M7583)Telios PharmaceuticalsOngoing
Dec 4, 2018A 3-part, randomized, double-blind, placebo-controlled phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285), a selective kit…Avapritinib (BLU-285)SanofiOngoing
Apr 28, 2014A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase 3…Masitinib (AB1010)AB SciencePending

FDA orphan designations

Approved first, then open designations, newest first
May 22, 2023AyvakitTreatment of adult patients with indolent systemic mastocytosis (ISM)Sanofi US Services Inc.Approved
Jun 16, 2021AyvakitTreatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis…Sanofi US Services Inc.Approved
Apr 28, 2017RydaptTreatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm…Novartis Pharmaceuticals CorporationApproved
Oct 19, 2006GleevecTreatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknownNovartis Pharmaceuticals CorporationApproved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.